These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10429958)

  • 1. Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity.
    Lipkowitz GS; Madden RL; Mulhern J; Braden G; O'Shea M; O'Shaughnessy J; Nash S; Kurbanov A; Freeman J; Rennke H; Germain M
    Transpl Int; 1999; 12(3):202-7. PubMed ID: 10429958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term renal function in heart transplant recipients receiving cyclosporine therapy.
    Goral S; Ynares C; Shyr Y; Yeoh TK; Johnson HK
    J Heart Lung Transplant; 1997 Nov; 16(11):1106-12. PubMed ID: 9402509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients.
    Lewis RM; Van Buren CT; Radovancevic B; Frazier OH; Janney RP; Powers PL; Golden DL; Giannakis JG; Macris MP; Kerman RH
    J Heart Lung Transplant; 1991; 10(1 Pt 1):63-70. PubMed ID: 2007172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
    Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
    Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors predicting the long-term success of maintenance cyclosporine monotherapy after kidney transplantation.
    Hurault de Ligny B; Toupance O; Lavaud S; Bauwens M; Peyronnet P; Le Meur Y; Ryckelynck JP; Jolly D; Leroux-Robert C; Touchard G
    Transplantation; 2000 Apr; 69(7):1327-32. PubMed ID: 10798748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine and long-term kidney graft survival.
    Opelz G; Döhler B
    Transplantation; 2001 Oct; 72(7):1267-73. PubMed ID: 11602854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
    Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic renal failure following liver transplantation: a retrospective analysis.
    Fisher NC; Nightingale PG; Gunson BK; Lipkin GW; Neuberger JM
    Transplantation; 1998 Jul; 66(1):59-66. PubMed ID: 9679823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of cyclosporine in renal-transplant recipients.
    Burke JF; Pirsch JD; Ramos EL; Salomon DR; Stablein DM; Van Buren DH; West JC
    N Engl J Med; 1994 Aug; 331(6):358-63. PubMed ID: 8028616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine microemulsion formulation (sigmasporin microral) effect as first-line immunosuppressant on renal functions at 3 years.
    Al Wakeel J; Shaheen FA; Al Alfi A; Abbas Fagir EH; Iman A; Nampoory MR; Al Mousawi MS; Said T; Abou Zeinab H; Shaker DS; Ghaedi BB
    Transplant Proc; 2012 Jan; 44(1):94-100. PubMed ID: 22310589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine.
    Medina-Pestana JO; Felipe CR; Park SI; Machado PG; Garcia R; Spinelli G; Silva LA; Santos CF; Tedesco-Silva H
    Transplant Proc; 2004 Mar; 36(2 Suppl):74S-79S. PubMed ID: 15041311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
    Aleksic I; Baryalei M; Busch T; Pieske B; Schorn B; Strauch J; Sîrbu H; Dalichau H
    Transplantation; 2000 Apr; 69(8):1586-90. PubMed ID: 10836367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.